[The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].
OBJECTIVE
To study the ciliotoxicity of nasalmucosal with nasal decongestant, in order to choose the appropriate nasal decongestant.


METHODS
(1) Selected 100 healthy volunteers, by using 0.05% hydrochloride oxymetazoline, 0.025% hydrochloride oxymetazoline, 1.0% ephedrine and 0.5% ephedrine for 7 days with sacchariu technique to test nasal mucociliary transport, and compared with the normal saline. (2) To observe the mucosa of inferior turbinate with Electron Microscopy.


RESULTS
After using nasal decongestant for 7 days, Mean nasal mucociliary transport rate (MTR) in 0.0500 hydrochloride oxymetazoline groups was (7.64+/-1.56) mm/min and (7.46+/-1.65) mm/min in 0.25% hydrochloride oxymetazoline groups, Mean nasal mucociliary transport rate (MTR) in 1.0% ephedrine groups was (4.73+/-2.03) mm/min and (4.38+/-2.04) mm/min in 0.5% ephedrine groups,The normal saline groups was (7.14+/-1.76) mm/min. MTR was obviously different (F = 16.50, P <0.01). (2)With electron microscopy, it was found that the cilia of epithelial cells were in good order, uniformed in hydrochloride oxymetazoline groups and exfoliated in ephedrine groups.


CONCLUSIONS
Ephedrine has ill effects on nasal mucosa; Hydrochloride oxymetazoline has neither effect on nasal mucosa, nor destroying the physical function of nose, it is an ideal nasal decongestant.
Teng
Yishu
Y
Department of Otorhinolaryngology, Hospital of Otorhinolaryngology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. tys118@163.com
Zhang
Xiangmin
X
Xu
Geng
G
Cai
Qian
Q
Xu
Jiajian
J
D000293:Adolescent; D000328:Adult; D004809:Ephedrine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009079:Mucociliary Clearance / Q000187:drug effects*; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000009:adverse effects*; D009297:Nasal Mucosa / Q000187:drug effects* / Q000502:physiology*; D010109:Oxymetazoline / Q000008:administration & dosage / Q000009:adverse effects*; D055815:Young Adult
D014663:Nasal Decongestants; D010109:Oxymetazoline; D004809:Ephedrine